高效液相色谱-高分辨轨道阱质谱联用法对兰索拉唑肠溶制剂的杂质谱研究
Impurity spectra of lansoprazole enteric-coated preparations by high performance liquid chromatography-high resolution orbital trap mass spectrometry
-
摘要: 采用高效液相色谱-高分辨轨道阱质谱联用检测方法，建立二维在线除盐检测方法对兰索拉唑肠溶制剂法定检验条件下检出的杂质进行结构推定，建立兼容质谱检测器的色谱方法对法检方法无法分离的杂质进行测定和结构推定，检出杂质结构的鉴定方法根据有无杂质对照品而异来推定其结构，以此考察不同企业间产品杂质谱的差异性。二维在线除盐方法的一维色谱条件同《中华人民共和国药典》（2020版）有关物质项下，二维质谱条件采用Waters C18 T3（2.1 mm × 100 mm，1.7 μm）色谱柱，0.1%甲酸水-乙腈流动相，梯度洗脱。兼容质谱的色谱条件采用Agilent Extend C18（4.6 mm × 150 mm， 5 μm）色谱柱，流动相A相：25 mmol/L乙酸铵，B相：25 mmol/L乙酸铵-乙腈（1∶4）[用冰乙酸调节pH至6.5]，梯度洗脱。二维在线除盐方法检出杂质9个，其中5个为已知杂质A ~ E，4个为未知杂质。兼容质谱检测器方法检出杂质14个，其中9个为未知杂质（4个与二维在线除盐方法结果一致，5个为该条件下新检出）。对未知杂质的结构进行了推测和来源归属。本文建立的两个高效液相色谱-高分辨轨道阱质谱联用检测方法对兰索拉唑制剂的质量控制和工艺评价具有指导意义。Abstract: Using high performance liquid chromatography and high resolution orbital trap mass spectrometry, a two-dimensional online desalting detection method was established to determine the structure of the impurities detected under the official testing conditions of lansoprazole enteric solution preparation, and a chromatographic method compatible with mass spectrometry was established to determine and presume the structure of the impurities that could not be separated by the the official testing method.The identification of impurity was to presume its structure according to the presence of impurity reference product, so as to investigate the difference of impurity spectrum of products from different manufacturers.The one-dimensional chromatographic conditions for the 2D online desalting method were the same as those in China Pharmacopoeia (2020) under relevant substances.Two-dimensional chromatography was performed on a Waters C18 T3 column (2.1 mm × 100 mm, 1.7 μm) with 0.1% formic acid in water-acetonitrile mobile phase and gradient elution.The chromatographic conditions for the compatible mass spectra were based on an Agilent Extend C18 (4.6 mm × 150 mm, 5 μm) column with mobile phase A: 25 mmol/L ammonium acetate and B: 25 mmol/L ammonium acetate-acetonitrile (1∶4) [pH adjusted to 6.5 with glacial acetic acid], with gradient elution. Nine impurities were detected by two-dimensional online desalting method, with 5 known impurities (A-E) and 4 unknown ones.14 impurities were detected by the compatible mass spectrometry method, with 9 unknown impurities (4 consistent with the results of two-dimensional online desalting method, and 5 newly detected).The structures and sources of the unknown impurities were deduced.The two detection methods of lansoprazole preparation by high-performance liquid chromatography-high resolution orbital trap mass spectrometry have guiding significance for quality control and process evaluation.
-
-
[1] Zong SY, Wang JK, Xiao Y, et al. Solubility and dissolution thermodynamic properties of lansoprazole in pure solvents[J]. J Mol Liq, 2017, 241: 399-406. [2] Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity[J]. Curr Pharm Des, 2013, 19(1): 67-75. [3] Li MH, Feng Q, Li XY, et al. Research progress of clinical applications and adverse reactions of lansoprazole[J]. Chin J Pharmacov (中国药物警戒)，2014,11(12): 729-731. [4] Gholve SB, Sangshetti JN, Bhusnure OG, et al. RP-HPLC method development and validation for the estimation of lansoprazole in presence of related substances by QbD approach[J]. J Pharm Res Int, 2021, 33(36A): 138-150. [5] DellaGreca M, Iesce MR, Previtera L, et al. Degradation of lansoprazole and omeprazole in the aquatic environment[J]. Chemosphere, 2006, 63(7): 1087-1093. [6] British Pharmacopoeia Commission. British Pharmacopoeia [S]. London: Medicines and Healthcare Products Regulatory Agency, 2022.[7] United States Pharmacopeia Convention. United States Pharmacopeia/ National Formulary [S]. Maryland: The Pharmaceutical Association, 2022.[8] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia:part 2 (中华人民共和国药典：二部) [S]. Beijing: China Medical Science Press, 2020: 283-285.[9] Yang L, Zhang Y, Zhu GF, et al. Synthesis of potential impurities of lansoprazole[J]. Chem Reag (化学试剂), 2020, 42(9): 1120-1124. [10] Shandilya DK, Israni R, Joseph PE, et al. Identification of oxidative degradation products of lansoprazole by using high resolution mass spectrometry spectral data[J]. Int J Anal Mass Spectrom Chromatogr, 2017, 5(3): 57-69. [11] Shankar G, Borkar RM, Suresh U, et al. Forced degradation studies of lansoprazole using LC-ESI HRMS and 1H NMR experiments: in vitro toxicity evaluation of major degradation products[J]. J Mass Spectrom, 2017, 52(7): 459-471. [12] Ramulu K, Rao BM, Rao NS. Identification, isolation and characterization of potential degradation product in lansoprazole drug substance[J]. RASāYAN J Chem, 2013, 6(4): 274-283. -
期刊类型引用(14)
1. 王经纬，陈晓颙，袁怡，刘晨曦，胡敏. 阿达帕林凝胶原研药与仿制药的流变学特性一致性考察. 药学前沿. 2025(01): 33-39 . 
百度学术
2. 方泽卿，罗华菲，朱慧勇，黄贺敏. 药用辅料用压敏胶流变学的研究进展. 中国医药工业杂志. 2025(03): 303-314 . 百度学术
3. 欧阳艺，陈昌蓉，江宇凯. 复合黄酮乳膏的流变学特性. 广东化工. 2025(07): 44-46+20 . 百度学术
4. 白明月，杨俊，胡秀云，臧可昕，米楠. 触变胶型口服混悬液的流变学测定样品处理方法研究与盐酸鲁拉西酮口服混悬液流变学特征评价. 药物评价研究. 2025(06): 1587-1595 . 百度学术
5. 刘超逸，高旋，王林波，陈晓萍，秦峰，吴晓鸾. 2类皮肤外用半固体制剂屈服应力测定方法的研究. 中国新药杂志. 2024(14): 1489-1495 . 百度学术
6. 荣娜娜，朱嘉亮，刘继华，王莹，吴静. HPLC法测定丁酸氢化可的松乳膏中有关物质. 大理大学学报. 2024(08): 46-52 . 百度学术
7. 陈倩倩，刘正平，李硕蕾，薛松，李大伟. 盐酸特比萘芬乳膏流变学性质的研究. 中国药师. 2024(08): 1296-1302 . 百度学术
8. 王丽丽，祝美华，陈建英. 软膏基质白凡士林的流变学性质研究. 食品与药品. 2024(06): 584-589 . 百度学术
9. 钱喜龙，王可为，刘政，周柳，马瑜璐，房方，章阳，王业皇，江滨，刘圣金. 基于确定性筛选设计优化榆皇生肌乳膏的制备工艺. 中国新药杂志. 2024(23): 2518-2528 . 百度学术
10. 刘晓纯，罗婷婷，戴洁，陈来成，何秋星. 美藤果发酵多肽对液晶乳液结构的影响（英文）. 日用化学工业(中英文). 2024(12): 1456-1464 . 百度学术
11. 杨凯丽，郭子硕，张翼，陈宛灵，王晓静，杜守颖，李鹏跃. 甘草酸凝胶的流变学性质及其对橙皮苷的增溶作用研究. 中草药. 2023(11): 3468-3479 . 百度学术
12. 方媛，刘子修，冯明庆，吴鹏，王培民，茆军. 三色散凝胶贴膏处方优化. 中成药. 2023(11): 3718-3723 . 百度学术
13. 郑荣蕾，杨放，刘睿鹏，张梅，田佩灵，刘涛. 喷膜剂成型过程及质量控制关键技术探讨. 成都大学学报(自然科学版). 2022(03): 225-229 . 百度学术
14. 李娇，刘变娥，高雪锋，秦敦忠，张宇，寇俊杰. 吡唑醚菌酯悬浮剂流变性与稳定性的关系研究. 现代农药. 2022(06): 19-27 . 百度学术
其他类型引用(5)
计量
- 文章访问数: 156
- HTML全文浏览量: 13
- PDF下载量: 296
- 被引次数: 19
下载:
